Telaprevir combination therapy in patients infected with hepatitis C virus genotype 4

Öz

Background: The sustained virological response (SVR) rate for genotype 4 (G4) HCV-infected patients after pegylated interferon (PegIFN) and ribavirin (RBV) treatment is approximately 60%. We aimed to investigate the efficacy and safety of telaprevir (TVR) in combination with PegIFN and RBV in patients infected with G4 HCV who were previously treated with PegIFN/RBV and failed to achieve SVR.

Material and Methods: The study included 10 patients: two prior relapsers, two prior partial responders, and six prior null responders to PegIFN/RBV treatment. The patients were given TVR/PegIFN/RBV for 12 weeks, followed by a 12-36 weeks PegIFN/RBV treatment. Rapid virological response (RVR), early virological response (EVR), extended rapid virological response (eRVR), SVR, and side effects of therapy were evaluated.

Results: The mean age of the patients was 48.90±12.52 years and seven were female. All of HCV isolates were typed as 4d. Interleukin (IL) 28B genotype was found CT in seven patients and two patients had cirrhosis. Treatment was stopped within four weeks because of the side effects in two patients. Three of the remaining eight patients (37.5%) achived HVR, RVR, and eHVR. SVR was obtained in two of these patients, but one patient relapsed. SVR rates were 25% in all patients.

Conclusion: TVR combination therapy had limited antiviral activity in this patient population. Further investigation of TVR combination therapy in patients with HCV G4 infection is warranted.

Anahtar Kelimeler

• Helicobacter pylori,babA2,cagA,gastric disorders

Kaynakça

1. Vo KP, Vutien P, Akiyama MJ, Vu VD, Ha NB, Piotrowski JI, et al. Poor sustained virological response in a multicenter real-life cohort of chronic hepatitis C patients treated with pegylated interferon and ribavirin plus telaprevir or boceprevir. Dig Dis Sci 2015; 60: 1045-1051.
2. Bozkurt I, Aygen B, Gökahmetoglu S, Yildiz O. Hepatitis C and occult hepatitis C infection among hemodialysis patients from Central Anatolia. J Pure Appl Microbiol 2014; 8: 435-440.
3. Aygen B, Yıldız O, Akhan S, Çelen MK, Ural O, Tekin Koruk S, et al. Retreatment of chronic hepatitis C infection with telaprevir: preliminary results in Turkey. Balkan Med J 2015; 32: 266-272.
4. Kamal SM, Nasser IA. Hepatitis C genotype 4: what we know and what we don’t yet know. Hepatology 2008; 47: 1371-1383.
5. Gökahmetoğlu S, Bozdayı M, Özbakır Ö, Aygen B, Özbal Y, Soyuer I, et al. Hepatitis C virus genotypes detected in Erciyes University. Journal of Turkish Society of Microbiology 2007; 37: 35-38.
6. Gökahmetoğlu S, Atalay MA, Kılınç A. Determination of the hepatitis C virus genotypes with “pyrosequencing” method. Erciyes Medical Journal 2011; 33: 99-102.
7. Ciccozzi M, Zehender G, Polat C, Lai A, Kayman T, Sorrentino C, et al. Phylogenetic analysis of HCV-4d in Turkey: the curious case of Kayseri province. J Med Virol 2014; 86:454-460.
8. Kayman T, Polat C, Ergör G, Abacioğlu YH. Characterization of HCV genotype 4d infections in Kayseri, Turkey. Turk J Med Sci 2015; 45: 547-552.

9. Matthews SJ, Lancaster JW. Telaprevir: A hepatitis C NS3/4A protease inhibitor. Clin Ther 2012; 34: 1857-1882.
10. Benhamou Y, Moussalli J, Ratziu V, Lebray P, De Backer K, De Meyer S, et al. Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial. J Infect Dis 2013; 208: 1000-1007.
11. Ishak K, Baptisa A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
12. Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012; 6: 409-435.
13. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
14. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444.
15. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
16. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
17. Murphy DG, Willems B, Deschenes M, Hilzenrat N, Mousseau R, Sabbah S. Use of sequence analysis of the NS5B region for routine genotyping of Hepatitis C virus with reference to C/E1 and 5’ untranslated region sequences. J Clin Microbiol 2007; 45: 1102-1112.
18. Laperche S, Lunel F, Izopet J, Alain S, Deny P, Duverlie G, et al. Comparison of hepatitis C virus NS5b and 5’noncoding gene sequencing methods in a multicenter study. J Clin Microbiol 2005; 43: 733-739.
19. Tamura K, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance and maximum parsimony methods. Mol Biol Evol 2011; 28: 2731-2739.
20. El Awady MK, Bader El Din NG, Tabll A, El Hosary Y, Abdel Aziz AO, El Khayat H, et al. IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients. World J Gastroenterol 2013; 19: 290-298.
21. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al; PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303.
22. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
23. Pérez-Parente D, Suárez-Ordóñez S, Suárez-Santamaría M, Morano-Amado LE. Hepatitis C genotype 1b and 4 cured after telaprevir-based therapy. Rev Esp Enferm Dig 2015; 107: 251.